BridgeBio Oncology (BBOT) Form 3: Director Reports Two Stock Options

Rhea-AI Filing Summary

Frank McCormick, a director of BridgeBio Oncology Therapeutics (BBOT), reported beneficial ownership consisting of two stock option awards. One option covers 141,870 shares exercisable in 2034 at $4.17 per share and a second option covers 8,497 shares exercisable in 2035 at $7.88 per share. Both awards vest monthly in equal installments as described in the filing. The Form 3 was submitted by one reporting person and includes a power of attorney.

Insights

Corporate Governance Expert

TL;DR: Routine director equity disclosure showing standard option grants with time-based monthly vesting, aligning interests with shareholders.

The Form 3 discloses two time-based stock option grants to a company director, totaling 150,367 underlying shares. The documented monthly vesting schedule is conventional for service-based awards and indicates alignment of the director's incentives with long-term company performance. There are no indications of acceleration clauses or atypical terms in the disclosed text.

Securities Analyst

TL;DR: Non-material routine Section 16 disclosure; options show potential future dilution but no immediate transfer of common stock.

The filing reports only derivative securities (stock options) exercisable in 2034 and 2035 at strike prices of $4.17 and $7.88, respectively. These are service-vested options that do not represent current common stock ownership until exercised. The disclosure is procedural under Section 16 and contains no additional compensatory or unusual financial terms beyond exercise prices and vesting cadence.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MCCORMICK FRANK

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	09/24/2034	Common Stock	141,870	$4.17	D
Stock Option (Right to Buy)	(2)	04/02/2035	Common Stock	8,497	$7.88	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of May 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Frank McCormick disclose on the Form 3 for BBOT?

He disclosed ownership of two stock options totaling 150,367 underlying shares with specified exercise prices and vesting schedules.

How many shares are covered by the options disclosed for BBOT?

The options cover a total of 150,367 shares (141,870 and 8,497 respectively).

What are the exercise prices of the disclosed BBOT options?

The disclosed exercise prices are $4.17 and $7.88 per share.

Do the disclosed options for BBOT vest immediately?

No. The filing states each option vests in 1/48th monthly installments beginning on the stated start dates.

Does the Form 3 show current common stock ownership for the reporting person?

No. The filing reports only derivative securities (stock options); it does not list current holdings of common stock.